[Perspectives for treatment of pulmonary fibrosis].
Conventional therapy of fibrogenic lung diseases, based mainly on the use of glucocorticoids or immunosuppressive, cytotoxic agents, does not usually protect before progression of disease and accumulation of the excess connective tissue in lungs. This article is a review of potential new therapies in the treatment of pulmonary fibrosis. Novel therapies emerged from the use of animal models of pulmonary fibrosis and recent advances in the cellular and molecular biology of inflammatory reaction involve the use of substances directed against the action of pathogenic agents: growth factors, cytokines or oxidants. Thus, future therapeutic strategies will be aimed at more selective and effective methods of controlling the key elements of pulmonary fibrosis.
Siemińska
A
A
Kliniki Chorób Płuc, Gruźlicy AM w Gdańsku.
D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use; D016207:Cytokines / Q000627:therapeutic use; D018450:Disease Progression; D005978:Glutathione / Q000008:administration & dosage; D006133:Growth Substances / Q000627:therapeutic use; D006801:Humans; D011658:Pulmonary Fibrosis / Q000628:therapy*
D000975:Antioxidants; D016207:Cytokines; D006133:Growth Substances; D005978:Glutathione